Guard Therapeutics International AB (GUARD) - Total Assets
Based on the latest financial reports, Guard Therapeutics International AB (GUARD) holds total assets worth Skr70.88 Million SEK (≈ $7.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guard Therapeutics International AB - Total Assets Trend (2008–2024)
This chart illustrates how Guard Therapeutics International AB's total assets have evolved over time, based on quarterly financial data. Also see GUARD market cap overview for the company's overall valuation and market capitalisation.
Guard Therapeutics International AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Guard Therapeutics International AB's total assets of Skr70.88 Million consist of 100.0% current assets and 0.0% non-current assets. Review Guard Therapeutics International AB (GUARD) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 97.2% |
| Accounts Receivable | Skr1.56 Million | 2.8% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Guard Therapeutics International AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Guard Therapeutics International AB for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guard Therapeutics International AB's current assets represent 100.0% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 97.2% of total assets in 2024, up from 10.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 12.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 2.8% of total assets.
Guard Therapeutics International AB Competitors by Total Assets
Key competitors of Guard Therapeutics International AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Guard Therapeutics International AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.87 | 6.26 | 14.02 |
| Quick Ratio | 4.87 | 6.26 | 14.02 |
| Cash Ratio | 4.79 | 5.54 | 0.00 |
| Working Capital | Skr56.31 Million | Skr63.50 Million | Skr84.67 Million |
Guard Therapeutics International AB - Advanced Valuation Insights
This section examines the relationship between Guard Therapeutics International AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -34.6% |
| Total Assets | Skr55.74 Million |
| Market Capitalization | $3.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guard Therapeutics International AB's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guard Therapeutics International AB's assets decreased by 34.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guard Therapeutics International AB (2008–2024)
The table below shows the annual total assets of Guard Therapeutics International AB from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr55.74 Million ≈ $6.00 Million |
-34.60% |
| 2023-12-31 | Skr85.23 Million ≈ $9.17 Million |
-57.93% |
| 2022-12-31 | Skr202.60 Million ≈ $21.80 Million |
+6.39% |
| 2021-12-31 | Skr190.44 Million ≈ $20.49 Million |
+108.76% |
| 2020-12-31 | Skr91.22 Million ≈ $9.82 Million |
+43.17% |
| 2019-12-31 | Skr63.71 Million ≈ $6.86 Million |
+133.59% |
| 2018-12-31 | Skr27.28 Million ≈ $2.94 Million |
-37.51% |
| 2017-12-31 | Skr43.65 Million ≈ $4.70 Million |
+2.77% |
| 2016-12-31 | Skr42.47 Million ≈ $4.57 Million |
-17.84% |
| 2015-12-31 | Skr51.69 Million ≈ $5.56 Million |
-10.83% |
| 2014-12-31 | Skr57.97 Million ≈ $6.24 Million |
+22.89% |
| 2013-12-31 | Skr47.17 Million ≈ $5.08 Million |
-1.37% |
| 2012-12-31 | Skr47.82 Million ≈ $5.15 Million |
+514.91% |
| 2011-12-31 | Skr7.78 Million ≈ $836.98K |
+96.59% |
| 2010-12-31 | Skr3.96 Million ≈ $425.74K |
+49.97% |
| 2008-12-31 | Skr2.64 Million ≈ $283.89K |
-- |
About Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more